Vendor Intelligence Report: Peptide Haven

Executive summary

Across 4 Finnrick lab tests, Peptide Haven has 0 pass / 4 fail — an overall pass rate of 0%. The record covers only retatrutide and tirzepatide; neither clears Finnrick’s pass threshold, and stricter-grading views do not turn either into a resilient profile. For those GLP purchases, Peptide Haven is not a Finnrick-backed first choice; the rest of the catalog remains untested by Finnrick.

Tirzepatide also carries a same-batch fill-control concern, made more important because the samples came through a vendor-submitted Launch context rather than blind marketplace purchases. The operating footprint adds recourse friction: a Delaware LLC with no disclosed owner, a Fayetteville coworking PMB, no Arkansas entity result despite Arkansas law/address language, and a GoDaddy privacy-shielded domain.

The storefront looks like a conventional outsourced WooCommerce shop, but source code points to Green.Money ACH/eDebit processing rather than ordinary card rails with Visa/Mastercard chargeback recourse. Catalog documentation is also thinner than the shop: investigators crawled 21 products but collected COAs for only four, all from Freedom Diagnostics, with no ISO/IEC 17025 accreditation found.

The promotion trail is small but consequential. Peptide Haven’s own TikTok sends buyers to OptPeptides with the code PEPHAVEN, while community review coverage remains thin. The full dossier separates documented linkage from ownership proof and shows which artifacts could confirm or weaken the sister-brand lead.

Inside the full report:

• Appendix A per-product Finnrick data and methodology-divergence charts for both tested products
• Corporate registry and address exhibits: Delaware file 7631534, Arkansas no-result search, and The Root Coworking PMB
• Source-code artifacts for Green.Money client ID 118665, Google tags, and the WooCommerce/GoDaddy stack
• COA coverage analysis across the 21-product crawl, including Freedom Diagnostics accreditation posture
• GLP-RT/GLP-TR product-identity review and tirzepatide batch-fill concern
• Promotion-network evidence covering X posts, coupon pages, Instagram lead, and the OptPeptides PEPHAVEN cross-promo

Risk assessment

• Product-quality reliability risk for Peptide Haven retatrutide and tirzepatide — high: Finnrick tested 4 samples across Retatrutide and Tirzepatide; 0 pass / 4 fail, current ratings 73.05% and 72.76%, with tirzepatide batch-fill variance noted in certificate review.
• COA coverage and lab-accreditation risk — high: Only 4 of 21 catalog products had COAs collected; Freedom Diagnostics testing found but no ISO/IEC 17025 accreditation; un-COA products include Melanotan-MTII.
• Ownership and recourse opacity risk — high: Delaware LLC file 7631534 has no public owner, the domain is privacy-protected, the Arkansas address is a coworking PMB, and no Arkansas registration was found.
• Payment-recoupment risk — high: Site source identified Green.Money client ID 118665 and ACH/eDebit processing; buyers lack ordinary credit-card chargeback protection for fulfillment or quality disputes.
• Product-identity and regulatory-continuity risk — medium: GLP-RT and GLP-TR labels obscure retatrutide and tirzepatide while URL slugs reveal the true products, consistent with payment/search/regulatory friction management.
• Affiliate-promotion and cross-brand confusion risk — medium: Official TikTok points to OptPeptides using PEPHAVEN, X/coupon promotion shows weak or no disclosure, and Peptide Haven publishes no authoritative channel or reseller list.